On January 4, 2021 BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies targeting specific pathogenic bacteria, reported that Jonathan Solomon, Chief Executive Officer, will participate in the following upcoming investor conferences (Press release, BiomX, JAN 4, 2021, View Source [SID1234573427]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: H.C. Wainwright BioConnect Conference
Dates: January 11-14, 2021
Time: Playback available 6 a.m. EST January 11
Webcast link: BiomX – HCW BioConnect Conference Playback
The webcast will also be available in the Events section of the BiomX website at www.biomx.com.

Event: Oppenheimer Virtual Banking Meeting
Dates: January 11-14, 2021
1×1 meetings only

On January 4, 2021 DURECT Corporation (Nasdaq: DRRX) reported that the sale of the LACTEL product line to Evonik closed and the $15 million payment was received on December 31, 2020 (Press release, DURECT, JAN 4, 2021, https://investors.durect.com/news-releases/news-release-details/durect-corporation-announces-closing-lactelr-absorbable-polymer?field_nir_news_date_value[min]=2021 [SID1234573426]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On January 4, 2021 Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, reported that John P. Butler, President and Chief Executive Officer, will present virtually at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, at 2:50 p.m. EST (Press release, Akebia, JAN 4, 2021, View Source [SID1234573425]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast and replay of Akebia’s presentation and associated Q&A will be available on the Investors section of the Company’s website at View Source

On January 21, 2021 Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, reported that CEO Stéphane Bancel will present an update on the Company and its pipeline of mRNA development programs at this year’s 39th annual J.P. Morgan Healthcare Conference (Press release, Moderna Therapeutics, JAN 4, 2021, View Source [SID1234573424]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mr. Bancel’s presentation will take place virtually on Monday, January 11th, 2021 at 4:30 p.m. ET. A live webcast will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of the webcast will be archived on Moderna’s website for 90 days following the presentation.

On January 4, 2021 Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, reported that management will participate in investor conferences through January 2021 (Press release, Autolus, JAN 4, 2021, View Source [SID1234573423]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

11 January 2021 – The company will present at the H.C. Wainwright BioConnect 2021 Conference which will be available on demand as of 6:00 am ET, 11 am GMT on Monday, January 11, 2021. The webcast will be available on the investor relations section of the Company’s website at Autolus.

13 January 2021 – The company will present at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 9:10 am ET, 2.10 pm GMT. The Company will host virtual one-on-one meetings at the J.P. Morgan event and a live audio webcast will be available on the investor relations section of the Company’s website at Autolus.
Archived replays will be available for a period of 30 days after the conferences.